{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Tumors", "query": { "condition": "Oral Tumors" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 2208, "total_pages": 221, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Tumors&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-27T07:55:01.665Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01881789", "title": "Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Oprozomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2013-10-28", "completion_date": "2019-09-23", "has_results": true, "last_update_posted_date": "2022-11-14", "last_synced_at": "2026-06-27T07:55:01.665Z", "location_count": 14, "location_summary": "Huntsville, Alabama • Burbank, California • Los Angeles, California + 11 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Burbank", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Salinas", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01881789" }, { "nct_id": "NCT07444268", "title": "How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Hematologic Malignancies" ], "interventions": [ { "name": "DSP-5336", "type": "DRUG" }, { "name": "[14C]-DSP-5336", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2026-03-26", "completion_date": "2026-08", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-06-27T07:55:01.665Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Houston, Texas", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07444268" }, { "nct_id": "NCT04161391", "title": "Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Medullary Thyroid Cancer", "RET Gene Mutation", "Metastatic Solid Tumor", "Advanced Solid Tumor" ], "interventions": [ { "name": "TPX-0046", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Turning Point Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2019-12-06", "completion_date": "2023-05-22", "has_results": true, "last_update_posted_date": "2024-06-13", "last_synced_at": "2026-06-27T07:55:01.665Z", "location_count": 20, "location_summary": "La Jolla, California • Orange, California • Aurora, Colorado + 15 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04161391" }, { "nct_id": "NCT00301418", "title": "Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma Multiforme", "Anaplastic Astrocytoma" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2006-03", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2016-02-10", "last_synced_at": "2026-06-27T07:55:01.665Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00301418" }, { "nct_id": "NCT04971226", "title": "A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive" ], "interventions": [ { "name": "Imatinib", "type": "DRUG" }, { "name": "Nilotinib", "type": "DRUG" }, { "name": "Bosutinib", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Asciminib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 405, "start_date": "2021-10-06", "completion_date": "2031-01-18", "has_results": true, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-06-27T07:55:01.665Z", "location_count": 13, "location_summary": "Denver, Colorado • Fort Myers, Florida • Tallahassee, Florida + 9 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04971226" }, { "nct_id": "NCT01106508", "title": "A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Recurrent or Refractory Medulloblastoma", "Locally Advanced or Metastatic Basal Cell Carcinoma" ], "interventions": [ { "name": "LEQ506", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2010-10", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-06-27T07:55:01.665Z", "location_count": 2, "location_summary": "Los Angeles, California • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01106508" }, { "nct_id": "NCT02727062", "title": "Smartphone Pain App for Assessing Oral Mucositis Pain in Patients", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Oral Mucositis" ], "interventions": [ { "name": "OM Pain App", "type": "DEVICE" }, { "name": "Accelerometer", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Stuart Wong", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-02-13", "completion_date": "2019-08-21", "has_results": false, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-06-27T07:55:01.665Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02727062" }, { "nct_id": "NCT00399659", "title": "Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Opioid-induced Constipation" ], "interventions": [ { "name": "Tegaserod", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 360, "start_date": "2006-11", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2012-05-01", "last_synced_at": "2026-06-27T07:55:01.665Z", "location_count": 57, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00399659" }, { "nct_id": "NCT00387920", "title": "Sunitinib in Treating Young Patients With Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Central Nervous System Metastases", "Childhood Central Nervous System Choriocarcinoma", "Childhood Central Nervous System Embryonal Tumor", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Central Nervous System Germinoma", "Childhood Central Nervous System Mixed Germ Cell Tumor", "Childhood Central Nervous System Teratoma", "Childhood Central Nervous System Yolk Sac Tumor", "Recurrent Childhood Central Nervous System Embryonal Tumor", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "sunitinib malate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "dynamic contrast-enhanced magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 35, "start_date": "2006-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-28", "last_synced_at": "2026-06-27T07:55:01.665Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00387920" }, { "nct_id": "NCT06315855", "title": "F.L.O.S.S. Project (Facilitated Lessons on Oral and Systemic Health in Survivors)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Oral Mucositis", "Periodontal Diseases", "Cancer" ], "interventions": [ { "name": "Telehealth Intervention (THI)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "25 Years to 75 Years" }, "enrollment_count": 100, "start_date": "2024-08-20", "completion_date": "2027-08-25", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-06-27T07:55:01.665Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06315855" } ] }